BUY Cipla — Sharekhan Research, 02 Sept 2025

BUYCipla Ltd.

Cipla share price target & all analyst calls

bySharekhan ResearchHorizon: NA (inferred 1 year)2 Sept 2025via Institutional / Brokerage Research

Entry₹1,569.2Inferred

Target₹1,754

Total upside +11.78%

Stop lossNot given

At expiry₹1,412.82 Sept 2026, 3:30 pm

Expired-9.97%auction close

Follow Sharekhan Research for new calls(55% target hit, 443 closed calls)Get alerts Watch CIPLA for new buy/sell callsGet alerts See 17 active Long-term calls on CIPLA See 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 2 Sept 2026

11 supporting17 neutral15 opposing

Supports the BUY call (11)

Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix

NewsCnbc-Tv18·1 Sept · today

Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm

NewsCnbc-Tv18·1 Sept · yesterday

Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets

NewsCnbc-Tv18·31 Aug · yesterday

Cipla Ltd has signed an exclusive licensing agreement with SBP Group for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC.

BSE · Company Update·31 Aug · yesterday

6 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·26 Aug · 1w ago

Neutral / worth noting (17)

US FDA classifies Cipla subsidiary’s New York facility inspection as ‘Voluntary Action Indicated’

NewsCnbc-Tv18·29 Aug · 4d ago

Cipla Pharma License Cancellation: FDA Withdraws Order After HC Raps It For Going "Overboard"

NewsNdtv-Profit·29 Aug · 4d ago

Cipla shares slip after USFDA observations; Citi says no earnings impact, target at ₹1,700

NewsCnbc-Tv18·26 Aug · 1w ago

Nifty, Sensex open lower on Iran sanctions, tech selloff; TCS, Eternal gain while Cipla, Maruti slip

NewsHbl·25 Aug · 1w ago

Cipla Ltd has received an order from the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench, allowing the Company Scheme Application for the amalgamation of its wholly-owned subsidiary, Inzper

BSE · Company Update·19 Aug · 2w ago

Weighs against the BUY call (15)

Cipla Pharma license cancellation: FDA withdraws order after Bombay HC raps it for going 'overboard'

NewsCnbc-Tv18·29 Aug · 3d ago

FDA Crackdown: Cipla Arm Loses Pune Drug Sales Licence For Storage Deficiencies, Illegal Ads

NewsNdtv-Profit·28 Aug · 4d ago

Cipla gets seven USFDA observations for Pithampur plant after follow-up inspection

NewsCnbc-Tv18·25 Aug · 1w ago

3 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·24 Jul · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cipla

All analyst calls on Cipla

More from Sharekhan Research

Every call and its outcome

BUY Cipla Ltd. — Sharekhan Research

AI Assessment

Other calls on Cipla

More from Sharekhan Research